Terms: = Chronic Myelogenous Leukemia AND YWHAE, P62258, 7531, ENSG00000108953, 14-3-3 epsilon, FLJ45465, MDS, MDCR, KCIP-1, 14-3-3E AND Treatment
154 results:
1. [Biological and clinical significance of TP53 mutations in myelodysplastic syndrome and acute myeloid leukemia].
Kojima K
Rinsho Ketsueki; 2023; 64(9):955-961. PubMed ID: 37793871
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Features of Clonal Cytogenetic Abnormalities in Philadelphia-negative Cells Developed During Tyrosine Kinase Inhibitor treatment.
Oiwa K; Lee S; Fujita K; Ueda T; Yamauchi T
Intern Med; 2024 Mar; 63(5):729-732. PubMed ID: 37468240
[TBL] [Abstract] [Full Text] [Related]
3. De nove Philadelphia chromosome-positive myelodysplastic syndromes with complex karyotype and p230
Ma J; Guan J; Chen B
Hematology; 2023 Dec; 28(1):2220220. PubMed ID: 37288817
[TBL] [Abstract] [Full Text] [Related]
4. [Radiation-induced hematopoietic disorders].
Ando K; Miyazaki Y
Rinsho Ketsueki; 2022; 63(9):981-990. PubMed ID: 36198562
[TBL] [Abstract] [Full Text] [Related]
5. ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.
Rahmani NE; Ramachandra N; Sahu S; Gitego N; Lopez A; Pradhan K; Bhagat TD; Gordon-Mitchell S; Pena BR; Kazemi M; Rao K; Giricz O; Maqbool SB; Olea R; Zhao Y; Zhang J; Dolatshad H; Tittrea V; Tatwavedi D; Singh S; Lee J; Sun T; Steidl U; Shastri A; Inoue D; Abdel-Wahab O; Pellagatti A; Gavathiotis E; Boultwood J; Verma A
Blood Cancer J; 2021 Sep; 11(9):157. PubMed ID: 34548471
[TBL] [Abstract] [Full Text] [Related]
6. Blastic plasmacytoid dendritic-cell neoplasia: a challenging case report.
Koerber RM; Held SAE; Vonnahme M; Feldmann G; Wenzel J; Gütgemann I; Brossart P; Heine A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):743-748. PubMed ID: 34529129
[TBL] [Abstract] [Full Text] [Related]
7. Prophylactic or Preemptive Low-Dose Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic Transplantation in Patients with High-Risk Acute myelogenous leukemia or Myelodysplastic Syndrome.
Guillaume T; Thépot S; Peterlin P; Ceballos P; Bourgeois AL; Garnier A; Orvain C; Giltat A; François S; Bris YL; Fronteau C; Planche L; Chevallier P
Transplant Cell Ther; 2021 Oct; 27(10):839.e1-839.e6. PubMed ID: 34224913
[TBL] [Abstract] [Full Text] [Related]
8. Bone marrow mesenchymal stromal cells in chronic myelomonocytic leukaemia: overactivated WNT/β-catenin signalling by parallel RNA sequencing and dysfunctional phenotypes.
Xu R; Huang X; Li C; Deng C; Li M; Wu P; Geng S; Lai P; Lu Z; Weng J; Du X
Br J Haematol; 2021 Jun; 193(5):928-940. PubMed ID: 33959953
[TBL] [Abstract] [Full Text] [Related]
9. Precision medicine in myeloid malignancies.
Westermann J; Bullinger L
Semin Cancer Biol; 2022 Sep; 84():153-169. PubMed ID: 33895273
[TBL] [Abstract] [Full Text] [Related]
10. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
Patnaik MM; Lasho T
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
[TBL] [Abstract] [Full Text] [Related]
11. Curcumol and FTY720 synergistically induce apoptosis and differentiation in chronic myelomonocytic leukemia via multiple signaling pathways.
Zhao M; Yang C; Chai S; Yuan Y; Zhang J; Cao P; Wang Y; Xiao X; Wu K; Yan H; Liu J; Sun S
Phytother Res; 2021 Apr; 35(4):2157-2170. PubMed ID: 33274566
[TBL] [Abstract] [Full Text] [Related]
12. [Optimization of ATG dose in haploid hematopoietic stem cell transplantation for hematologic malignancies].
Zhou X; Lu X; Tang L; Yan H; Chen WL; Shi W; Zhong ZD; You Y; Xia LH; Hu Y; Wang HF
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):557-563. PubMed ID: 32810962
[No Abstract] [Full Text] [Related]
13. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment.
McCullough KB; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101130. PubMed ID: 32460984
[TBL] [Abstract] [Full Text] [Related]
14. chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approaches.
Asnafi AA; Deris Zayeri Z; Shahrabi S; Zibara K; Vosughi T
J Cell Physiol; 2019 May; 234(5):5798-5806. PubMed ID: 30430567
[TBL] [Abstract] [Full Text] [Related]
15. Adoptive Immunotherapy with Cord Blood for the treatment of Refractory Acute myelogenous leukemia: Feasibility, Safety, and Preliminary Outcomes.
Gergis U; Frenet EM; Shore T; Mayer S; Phillips A; Hsu JM; Roboz G; Ritchie E; Scandura J; Lee S; Desai P; Samuel M; Ball J; Blanco A; Romeo C; Albano MS; Dobrila L; Scaradavou A; van Besien K
Biol Blood Marrow Transplant; 2019 Mar; 25(3):466-473. PubMed ID: 30414955
[TBL] [Abstract] [Full Text] [Related]
16. Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
Abaza Y; Hidalgo-Lopez JE; Verstovsek S; Jabbour E; Ravandi F; Borthakur G; Estrov Z; Alvarado Y; Burger J; Schneider H; Soltysiak KA; Wei Y; Kantarjian HM; Bueso-Ramos CE; Garcia-Manero G
Leuk Res; 2018 Oct; 73():78-85. PubMed ID: 30245189
[TBL] [Abstract] [Full Text] [Related]
17. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.
Loghavi S; Sui D; Wei P; Garcia-Manero G; Pierce S; Routbort MJ; Jabbour EJ; Pemmaraju N; Kanagal-Shamanna R; Gur HD; Hu S; Zuo Z; Medeiros LJ; Kantarjian HM; Khoury JD
Blood Adv; 2018 Aug; 2(15):1807-1816. PubMed ID: 30054307
[TBL] [Abstract] [Full Text] [Related]
18. Myeloid Neoplasms Following Solid Organ Transplantation: Clinicopathologic Studies of 23 Cases.
Wu B; Ingersoll K; Jug R; Yang LH; Luedke C; Lo A; Su P; Liu X; Rehder C; Gong J; Lu CM; Wang E
Am J Clin Pathol; 2017 Dec; 149(1):55-66. PubMed ID: 29228125
[TBL] [Abstract] [Full Text] [Related]
19. [Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)].
Yafour N; Beckerich F; Bulabois CE; Chevallier P; Daguindau É; Dumesnil C; Guillaume T; Huynh A; Levrat SM; Menard AL; Michallet M; Pautas C; Poiré X; Ravinet A; Yakoub-Agha I; Bazarbachi A
Bull Cancer; 2017 Dec; 104(12S):S84-S98. PubMed ID: 29179894
[TBL] [Abstract] [Full Text] [Related]
20. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
Molenaar RJ; Pleyer C; Radivoyevitch T; Sidana S; Godley A; Advani AS; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Angelini D; Maciejewski JP; Majhail N; Sekeres MA; Mukherjee S
Leukemia; 2018 Apr; 32(4):952-959. PubMed ID: 29104287
[TBL] [Abstract] [Full Text] [Related]
[Next]
